Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis - Wikidata - wikimedia - TriplyDB

Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis

Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis

http://www.wikidata.org/entity/Q27004079

about

Progressive multiple sclerosis Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis.Mindfulness-based interventions in multiple sclerosis: beneficial effects of Tai Chi on balance, coordination, fatigue and depression.The role of MRI in the evaluation of secondary progressive multiple sclerosis.Cognition and fatigue in patients with relapsing multiple sclerosis treated by subcutaneous interferon β-1a: an observational study SKORE Peginterferon beta-1a reduces disability worsening in relapsing-remitting multiple sclerosis: 2-year results from ADVANCE.Skeletal muscle mitochondrial capacity in people with multiple sclerosis.Acceptance of the extracare program by Beta interferon-treated patients with multiple sclerosis: results of the explore study Detection of postural sway abnormalities by wireless inertial sensors in minimally disabled patients with multiple sclerosis: a case-control study.Motor network efficiency and disability in multiple sclerosis.Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis.Defining Disease Activity and Response to Therapy in MS.Improvements in cognition, quality of life, and physical performance with clinical Pilates in multiple sclerosis: a randomized controlled trial.A comparative analysis of Patient-Reported Expanded Disability Status Scale tools.Quantitative measures of walking and strength provide insight into brain corticospinal tract pathology in multiple sclerosis.Affective Temperament Profiles in Patients with Multiple Sclerosis: Association with Mood Disorders.Therapeutic Targets for Multiple Sclerosis: Current Treatment Goals and Future Directions.Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study.Justification for conducting neurological clinical trials as part of patient care within private practice.The importance of a multi-disciplinary perspective and patient activation programmes in MS management.Role of Oligodendrocyte Dysfunction in Demyelination, Remyelination and Neurodegeneration in Multiple Sclerosis.Smokers with MS have greater decrements in quality of life and disability than non-smokers.Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes.Cardiopulmonary fitness is related to disease severity in multiple sclerosis.Utilization of the Expanded Disability Status Scale as a distinctive instrument for walking impairment in persons with multiple sclerosis with mild disability.CSF profile in primary progressive multiple sclerosis: Re-exploring the basics.The Role of T1-Weighted Derived Measures of Neurodegeneration for Assessing Disability Progression in Multiple Sclerosis.Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: Current views and new vistas.Evaluation of neurological changes in secondary progressive multiple sclerosis patients treated with immune modulator MIS416: results from a feasibility study.Perceptions on the value of bodily functions in multiple sclerosis.Multiple Sclerosis: Associations Between Physical Disability and Depression Are Not Mediated by Self-Reported Physical Activity.Cognitive clinico-radiological paradox in early stages of multiple sclerosis.Clinical outcome measures for progressive MS trials.Changes in structural network are associated with cortical demyelination in early multiple sclerosis.Can resistance training impact MRI outcomes in relapsing-remitting multiple sclerosis?Alemtuzumab Improves Cognitive Processing Speed in Active Multiple Sclerosis-A Longitudinal Observational Study.A Multiple Treatment Comparison of Eleven Disease-Modifying Drugs Used for Multiple Sclerosis.Differences in the Reponses to Apheresis Therapy of Patients With 3 Histopathologically Classified Immunopathological Patterns of Multiple Sclerosis.Eye Movement Abnormalities in Multiple Sclerosis: Pathogenesis, Modeling, and Treatment.

P2860

Q26861772-894095D0-91CB-4A00-BC22-3CF5F6654FD1 Q27000269-2A471421-D7DC-461D-BE99-1B32DB479EAA Q30277106-14D4C077-00E4-4914-8AD8-DCBBA1D03F17 Q30599387-7F69AA7C-328A-46BC-BEFB-CDA89F5265A7 Q31033345-4830DC42-435A-4BDC-8E1F-663DCCC44467 Q33589940-2B5BFF0E-AFFE-40B4-A467-1AE2F4334AE2 Q33589958-C81E7FEC-BC10-4F55-AA1F-E51BAC0737AE Q33613281-C6164ABA-C365-4948-99CE-86C0CC82A70F Q35100869-723BB2FD-6060-410A-BF36-775E2F379C9E Q36015734-915D1127-23EE-4F2D-BDFC-BD12C13E32DD Q36156672-11D9BFDB-48F2-4146-A252-E30B9757162C Q36353053-42226EAD-5F0C-4362-8C9C-FB7C14C312E3 Q36357501-AF2FABB0-2EE8-4E02-B73F-76DB95C711BC Q36829331-52490DF7-2D46-4EE4-9AE5-ABBABCCB7E91 Q37241679-7956811D-DFF6-4224-B5D8-69E4BB6F87C2 Q37682770-4CB280A1-946F-4BB7-9889-F3406720AF16 Q37703748-753C9304-7ABD-46A5-B141-5506C4B76B3A Q38666303-B2F12AC5-978C-41C4-879A-4C5DDFEF18DD Q38758444-C8E7C95E-797F-45F7-B425-4A6D1D79B1FA Q38797002-66CFF428-64F8-49D5-A275-F672E41B331D Q38910577-E1A69EFC-5A2E-4E2B-B7E0-2E3818A4F98B Q39091396-A2A180FB-BE00-4D89-A493-87E234AF187E Q40393188-37FFBBC5-0C60-4FA7-A087-1AFDDE477E5B Q40542938-02130C92-C137-4972-A82B-493132705708 Q40899032-593A045D-3AD4-4C95-9B7B-499CD841567B Q40902038-25D9D2FA-3108-423F-9CC2-02FF4CE7B85E Q41349564-A7E1343C-17BE-4893-9369-467973F42FA0 Q41475478-E80BBB68-88D4-4C91-84A7-ED7C334106C0 Q42515742-CF883007-6FDC-41EA-9DB0-2554DFC89E0C Q47103678-601DD8C7-C962-45BC-B6CC-7C169C7B39CC Q47567504-9AB4CADB-84F2-4A2E-8504-FB879B9057D0 Q47724130-DDEA71FD-C29D-458C-B98F-45088AC6B731 Q47835663-05A90F7E-E0FA-4995-9BE8-16E23853623D Q47892293-D8091321-F660-46F6-A26D-1E8637189C03 Q48091920-1DC34554-2316-457E-92AB-322479048377 Q48175695-3C28F1C1-C4D7-46F4-A231-7F6597F60AB8 Q49539768-288B5F8F-A653-46E4-9233-30054AF5B5B8 Q50111623-FB3D3EBE-86FE-40A9-8ABF-31D5F7538927 Q50194965-C3697730-ECE9-4817-9F65-2301FE3AD561 Q50307981-D31CACA2-AD87-4E2A-9AB0-60BF90CA3CFA

P2860

Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis

http://www.wikidata.org/entity/Q27004079

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Systematic literature review a ...... tients with multiple sclerosis

@ast

Systematic literature review a ...... tients with multiple sclerosis

@en

Systematic literature review a ...... tients with multiple sclerosis

@nl

type

label

Systematic literature review a ...... tients with multiple sclerosis

@ast

Systematic literature review a ...... tients with multiple sclerosis

@en

Systematic literature review a ...... tients with multiple sclerosis

@nl

prefLabel

Systematic literature review a ...... tients with multiple sclerosis

@ast

Systematic literature review a ...... tients with multiple sclerosis

@en

Systematic literature review a ...... tients with multiple sclerosis

@nl

P1433

Q27004079-89906078-A724-4379-A730-557905C935ED

P1476

Q27004079-E0C6AC9E-E38C-4F6B-B4E8-BE083BE1FE34

P2093

Q27004079-A2D0FEEF-AF7D-44F0-BA53-778BEF1AE391

Q27004079-A8D2CFE7-188B-486B-9CBF-5FC4B12506FF

Q27004079-C921CD08-EAA2-467D-BF6D-E2071F24241F

Q27004079-DCAFB790-7247-4077-AC1C-C88B07B69B15

Q27004079-E73F3381-27B9-4C5B-8594-30A97CA26B2E

P275

Q27004079-BF01A450-79F5-49F3-8BF1-AD90BDBB2B00

P2860

Q27004079-03D75A72-A876-4993-B7E3-187B442EDBBA

Q27004079-087CA8CE-22B0-48C9-AAFE-7DCC03824163

Q27004079-0B1F65CF-98F0-4E0B-AD3C-7589B3F8ADC2

Q27004079-0B9C77BC-DFC1-4C1C-AA56-22B0A6021EA8

Q27004079-0CEEFED1-E3EC-4E32-8255-7C2FB3BFBAFC

Q27004079-1709BB1E-BA6E-4521-BB56-906B12543D13

Q27004079-1A501D8C-221D-41EF-8409-08CBD25B95C4

Q27004079-1DE81108-5F76-406C-919A-3A1B570FC25C

Q27004079-2BABB8FC-FDBE-47AD-806C-DDFE501D2D9E

Q27004079-2BD9B61B-4FCE-4675-AAA0-817CCC064E20

P2888

Q27004079-65989DC2-3D4F-476A-8C01-AB9447DE401B

P304

Q27004079-F9E0795B-0A22-414F-A312-AA7FD815BCDD

P31

Q27004079-97D84FD6-0C7B-4BFD-85EA-84AFEF8BD6C3

Q27004079-B223F963-9F01-47CD-B5BC-73A7A4CC9CD8

P3181

Q27004079-FFB88C6D-ED06-4EE9-A654-DC8AF2790FEF

P356

Q27004079-003BE2F7-4BE5-4144-8814-8D30328433F6

P407

Q27004079-756673F3-E99A-4D2F-8EE5-42C8DE53ADA1

P478

Q27004079-44994765-472E-4628-B621-F5638609D410

P5008

Q27004079-6F490057-32D4-4135-BC49-2854E058CE74

P577

Q27004079-CDB29E15-7C68-4D78-921C-68DFBD87C0CB

P5875

Q27004079-E68DEB09-7116-47CB-AE33-AC312297D3BD

P6179

Q27004079-593CCC20-A96F-41E4-A201-7DEF6526B900

P698

Q27004079-B0F3A86F-2914-4295-8E82-9AFD5CD96519

P921

Q27004079-02C39992-7B4A-4455-999B-5D4B8F72FABB

Q27004079-476B792B-16AE-4B33-9CD7-BB79745F4E44

Q27004079-C21C8A0B-883A-454A-8FF1-53DF68685F8E

P932

Q27004079-DBD25779-131D-438A-AA36-70D278A186FB

P3181

P356

1471-2377-14-58

P1433

P1476

Systematic literature review a ...... tients with multiple sclerosis

@en

P2093

Franz-Werner Dippel

http://www.w3.org/2001/XMLSchema#string

Mathias Maeurer

http://www.w3.org/2001/XMLSchema#string

Sandra Meyer-Moock

http://www.w3.org/2001/XMLSchema#string

Thomas Kohlmann

http://www.w3.org/2001/XMLSchema#string

You-Shan Feng

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.0 Generic

P2860

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Quantification of impairment in MS: discussion of the scales in use

The Multiple Sclerosis Functional Composite: a new clinical outcome measure for multiple sclerosis trials

Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test.

The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force.

Challenges to clinical trials in multiple sclerosis: outcome measures in the era of disease-modifying drugs.

P2888

1471-2377-14-58

P304

58

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4956744

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/1471-2377-14-58

http://www.w3.org/2001/XMLSchema#string

P407

P478

14

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2014-03-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261101738

http://www.w3.org/2001/XMLSchema#string

P6179

1021497912

http://www.w3.org/2001/XMLSchema#string

P698

24666846

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis

P932

3986942

http://www.w3.org/2001/XMLSchema#string